According to the recent discovery that STAT3 inhibitors may improve the outcome of chemotherapy in cancer patients (Yang et al., 2015; Zhao et al., 2016), it is tempting to speculate that the supporting role of progranulin on STAT3 activity might be the reason, or among the reasons, underlying such an effect. Here, GRN is linked to cancer.